IMPROVED IMMUNOGENICITY OF RECOMBINANT VACCINIA VIRUS-ANCHORED GP120 LACKING GP41

被引：7

作者：

JIN, Y

GIRI, C

KLUTCH, MJ

SHEPP, D

WRIGHT, SE

机构：

[1] VAMC 111,6010 AMARILLO BLVD W,AMARILLO,TX 79106

[2] TEXAS TECH UNIV,HLTH SCI CTR,DEPT INTERNAL MED,LUBBOCK,TX 79430

[3] DHHS,FDA,CBD,OBRR,DIV VIROL,BETHESDA,MD

[4] TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,LUBBOCK,TX 79430

来源：

VACCINE | 1993年 / 11卷 / 13期

基金：

美国国家卫生研究院;

关键词：

IMMUNOGENICITY; FUSION PROTEIN;

D O I：

10.1016/0264-410X(93)90095-F

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To produce a vaccine against human immunodeficiency virus-1 with improved immunogenicity, the transmembrane and cytoplasmic tail regions of human immunodeficiency virus-1 were replaced with those of the Vesicular Stomatitis Virus glycoprotein, and cloned into vaccinia virus. This recombinant vaccinia virus, vvE13, was compared to one expressing full length envelope gp160, vvE1. Env products of both were located on the cell surface. Antibody response, lymphocyte proliferation and cytotoxicity were better with vvE13 than with vvE1 inoculated mice.

引用

页码：1280 / 1282

页数：3

共 18 条

[1]

BRUNNER KT, 1976, IN VITRO METHODS CEL, P423

[2] ENHANCED IMMUNITY TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE ELICITED BY A COMBINED VACCINE REGIMEN CONSISTING OF PRIMING WITH A VACCINIA RECOMBINANT EXPRESSING HIV ENVELOPE AND BOOSTING WITH GP160-PROTEIN [J].